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Abstract
Background: Deregulation of cellular energetic metabolism was recently pointed out as a hallmark of cancer cells.
This deregulation involves a metabolic reprogramming that leads to a high production of lactate. Lactate efflux,
besides contributing for the glycolytic flux, also acts in the extracellular matrix, contributing for cancer malignancy,
by, among other effects, induction of angiogenesis. However, studies on the interplay between cancer metabolism
and angiogenesis are scarce. Therefore, the aim of the present study was to evaluate the metabolic and vascular
molecular profiles of cervical adenocarcinomas, their co-expression, and their relation to the clinical and pathological
behavior.
Methods: The immunohistochemical expression of metabolism-related proteins (MCT1, MCT4, CD147, GLUT1 and
CAIX) as well as VEGF family members (VEGF-A, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2 and VEGFR-3) was assessed in a
series of 232 cervical adenocarcinomas. The co-expression among proteins was assessed and the expression profiles
were associated with patients’ clinicopathological parameters.
Results: Among the metabolism-related proteins, MCT4 and CAIX were the most frequently expressed in cervical
adenocarcinomas while CD147 was the less frequently expressed protein. Overall, VEGF family members showed a
strong and extended expression with VEGF-C and VEGFR-2 as the most frequently expressed and VEGFR-1 as the less
expressed member. Co-expression of MCT isoforms with VEGF family members was demonstrated. Finally, MCT4 was
associated with parametrial invasion and HPV18 infection, CD147 and GLUT1 with distant metastasis, CAIX with tumor
size and HPV18 infection, and VEGFR-1 with local and lymphnode metastasis.
Conclusions: The results herein presented provide additional evidence for a crosstalk between deregulating cellular
energetics and inducing angiogenesis. Also, the metabolic remodeling and angiogenic switch are relevant to cancer
progression and aggressiveness in adenocarcinomas.
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Background
Human papillomavirus (HPV) is a well-recognized causal
agent for cervical cancer development as well as for anal,
head and neck, penile cancers, among other malignancies
[1]. Cervical cancer is a serious problem for developing
countries’ public health authorities worldwide, due to the
high annual rates of incidence and mortality. Despite sev-
eral efforts in introducing screening programs, poor coun-
tries fail to reduce the effects of cervical cancer due to
innumerous problems related to cultural aspects, lack of
human resources and infrastructure, lack of political com-
mitment and limited economic investments [2]. HPV
vaccination is a promising tool to reduce the mortality
and iniquity that is related to HPV-induced cancer, but
the impact of primary prevention is a long-term invest-
ment and the costs are still over the possibility to be ef-
fectively implemented in underserved regions [3]. The last
Globocan publication from the International Agency for
Research on Cancer still pointed out cervical cancer as the
3rd more frequent malignancy in developing countries.
There are almost 500,000 new cases/year and 250,000
deaths in the World; circa 80 % of all cases occurs in de-
veloping/poor countries [4].
The development of cervical cancer from HPV infection
is frequently an enduring process that takes more than ten
years and involves different molecular pathways to effect-
ively occur [5]. Successful screening programs reduced the
incidence of squamous cell carcinoma, the most frequent
cervical cancer histological subtype, but not of cervical
adenocarcinoma, less frequent, which incidence is con-
stantly rising. This is still a worrying question to be solved
because cervical adenocarcinoma have a more aggressive
biological behavior as compared with squamous cell carcin-
oma, with poorer prognosis and decreased survival rates.
Part of these differences is attributed to distinctive molecu-
lar patterns but this topic is not fully understood [6].
The deregulation of cellular energetic metabolism was
recently pointed out as a hallmark of cancer cells. This de-
regulation involves metabolic reprogramming where can-
cer cells, even in the presence of oxygen, largely limit their
energetic metabolism to glycolysis, followed by pyruvate
conversion into lactate (known as the Warburg effect), in-
stead of pyruvate utilization in the mitochondria for Krebs
cycle followed by oxidative phosphorylation, a much more
energetically favorable metabolic pathway [7]. To allow
continuous glycolytic flux, cancer cells must promote the
efflux of the accumulating lactate. As a result, cancer cells
upregulate the plasma membrane transporters responsible
for lactate efflux—monocarboxylate transporters (MCTs)
[8]. MCTs are a family of 14 members but only isoforms
1–4 transport monocarboxylates, including lactate, coupled
with a proton [9]. In this context, MCT1 and MCT4, along
with their chaperone CD147 [10], emerge as key proteins
in the metabolic reprogramming of cancer cells, being
pointed out as potential therapeutic targets for cancer
therapy [8, 11, 12]. Other important proteins play key
roles in the metabolic reprogramming of cancer cells,
including the glucose transporter 1 (GLUT1) and the
pH regulator carbonic anhydrase IX (CAIX) [12].
Lactate efflux, besides contributing to the glycolytic flux
for energy and anabolic intermediate production, also de-
tains an important role in the extracellular matrix, contrib-
uting to cancer malignancy [13]. Actually, another hallmark
of cancer, induction of angiogenesis, is included in the ef-
fects of lactate in the extracellular matrix [7]. The basis for
this induction is a lactate-induced secretion of vascular
endothelial growth factor (VEGF), which induces angiogen-
esis [13]. In angiogenesis, new blood vessels grow from pre-
existing endothelial cells providing the substrate necessary
for cancer cells’ growth and spread [14]. VEGF, also know
as VEGF-A, can induce angiogenesis in physiological and
pathological conditions [15], and is the most well know
member of a family composed also of VEGF-B, VEGF-
C, VEGF-D and placental growth factor (PlGF) [16].
This group of highly conserved factors regulates vasculo-
genesis, hematopoiesis, angiogenesis, lymphangiogenesis
and vascular permeability [17, 18]. Different members of
this growth factor family have distinct biological function,
different receptors and diverse expression patterns [19].
The family also includes three tyrosine kinase receptors:
VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 (Flt-4).
VEGF-A binds to VEGFR-1 (vascular endothelial growth
factor receptor 1) and VEGFR-2, VEGF-B binds to VEGFR-
1, and both VEGF-C and VEGF-D bind to VEGFR-2 and
VEGFR-3 [18, 20]. Nowadays, the VEGF family members
and their receptors are considered important therapeutic
targets [21, 22] and increased expression of these proteins
in tumors has been associated with poor prognosis and in-
creased risk of recurrence or metastasis in several types of
cancers [23, 24]. Currently, several pro- or anti-angiogenic
drugs have been approved by the FDA or are in clinical tri-
als [25].
Since studies on the interplay between cancer metabolism
and angiogenesis are scarce, the aim of the present study
was to evaluate the metabolic and vascular molecular pro-
files of cervical adenocarcinomas and the possible crosstalk
between these two hallmarks of cancer. For that, the immu-
nohistochemical expression of a variety of metabolism-
related proteins and VEGF family members was evaluated
in a series of cervical adenocarcinomas, the possible co-
expression between metabolism-related proteins and VEGF
family members was tested and the expression profiles was
associated with the clinicopathological tumor behavior.
Methods
Human cervical adenocarcinoma samples
The series analyzed included 232 formalin-fixed paraffin-
embedded cervical adenocarcinomas, retrieved from the
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files of Araújo Jorge Hospital and the Pathology Depart-
ment of the School of Medicine of the Federal University
of Goiás, Goiania, in Goiás State, Brazil. Samples were
organized into tissue microarrays (TMA), ranging from
262 to 320 tumor cores (0.6 mm diameter each), also in-
cluding several control samples (normal kidney and pla-
centa). Each case was represented in the TMA by at least
two cores. Clinicopathological data included age at diag-
nosis (mean 48 years), tobacco use, FIGO classification,
tumor grade, tumor size, parametrial invasion, local,
lymphnode and distant metastasis, and survival. Detailed
information about the clinicopathological data is presented
in Table 1. The present study was approved by the hospital
ethics committee “Comitê de Ética em Pesquisa do Hos-
pital das Clínicas” of the Federal University of Goiás”, ref.
050/2011. Since this was a retrospective study with min-
imal risk to the participants (characterized by the breach of
confidentiality), no patient written consent was obtained
but patient's identity was protected.
HPV genotyping
DNA from archived formalin-fixed paraffin-embedded
samples was extracted with xylene, followed by two washes
with ethanol 100 % and 50 %, respectively, and the dried
pellet was incubated with 300 μl proteinase-K, overnight,
at 56 °C. After purification with fenol:chloroform:isoamylic
alcohol (25:24:1), the DNA was recovered and diluted in
water, and concentration determined in Nanodrop 2000
(Thermo Scientific, Waltham, MA, USA). DNA quality
was accessed by globin PCR using PCO3/PCO4 primers,
according to Saiki et al. [26]. HPV genotyping was based
on the L1 region of HPV genome, with SPF10 primers
from INNO-LiPA-genotyping assay (Innogenetics, Ghent,
Belgium) that identify 28 different genotypes. Results are
presented in Table 1.
Immunohistochemistry
MCT1 and CD147 immunohistochemistry was performed
according to the avidin-biotin-peroxidase complex method
(R.T.U. VECTASTAIN Elite ABC Kit (Universal), Vector
Laboratories, Burlingame, CA, USA), as previously de-
scribed [27]. Immunohistochemistry for MCT4, GLUT1
and CAIX was performed according to the streptavidin-
biotin-peroxidase complex principle (Ultravision Detection
System Anti-polyvalent, HRP, Lab Vision Corporation,
Fremont, CA, USA), as previously described [28, 29].
Appropriate serum controls were used as negative
controls (N1698 and N1699, Dako, Carpinteria, CA,
USA). Colon carcinoma tissue was used as positive
control for MCT1, MCT4 and CD147, head and neck
cancer was used for GLUT1 and normal stomach was
used for CAIX. Tissue sections were counterstained
with hematoxylin and permanently mounted. Please
Table 1 Clinicopathological data of the cervical adenocarcinoma
patients
Variable n %
Tobacco use (n = 117)
No 83 70.9
Yes 34 29.1
FIGO (n = 93)
I 49 52.7
II + III 44 47.3
Grade (n = 201)
Low grade (I) 118 58.7
High grade (II e III) 83 41.3
Tumor size (n = 36)
<4 cm 27 75.0
>4 cm 9 25.0
Parametrial invasion (n = 51)
Absent 21 41.2
Present 30 58.8
Local metastasis (n = 98)
Absent 73 74.5
Present 25 25.5
Lymphnode metastasis (n = 81)
Absent 68 84.0
Present 13 16.0
Distant metastasis (n = 126)
Absent 107 84.9
Present 19 15.1









18, 45 2 1.0
11 1 0.5
16, 45, 52 1 0.5
16, 18, 11 1 0.5
16, 74 1 0.5
16, 52 1 0.5
16, 11, 52 1 0.5
16, 45 1 0.5
16, 39 1 0.5
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refer to Table 2 for detailed aspects about each anti-
body used.
For VEGFs immunohistochemical analyses, the immu-
nohistochemical staining was performed automatically
with Ventana Benchmark® XT (Ventana Medical Systems,
Tucson, AZ, USA), following manufacturer’s guidelines
and then counterstained with hematoxylin and perman-
ently mounted. Negative controls were obtained by omit-
ting the primary antibody incubation step and normal
tonsils were used as positive control. Please refer to Table 2
for detailed aspects about each antibody used.
Immunohistochemical evaluation
Sections were scored semi-quantitatively for expression
in cancer cells as follows: 0: 0 % of immunoreactive cells;
1: <5 % of immunoreactive cells; 2: 5-50 % of immunore-
active cells; and 3: >50 % of immunoreactive cells. Also,
intensity of staining was scored semi-qualitatively as fol-
lows: 0: negative; 1: weak; 2: intermediate; and 3: strong.
The final score was defined as the sum of both parame-
ters (extension and intensity), and, for the metabolism-
related proteins, grouped as negative (score 0 and 2) and
positive (score 3–6), as previously described [27], while,
for VEGF family members, the final score was defined
as negative (score 0–5) and positive (score 6). Protein
expression in the different localizations (cytoplasm, plasma
membrane and nucleus) was considered. Two independent
observers (ALF and EAG) performed immunohistochemi-
cal evaluation blindly and discordant results were discussed
in a double-head microscope to determine the final score.
Statistical analysis
Data were stored and analyzed using the IBM SPSS Statis-
tics software (version 20, IBM Company, Armonk, NY).
All comparisons were examined for statistical significance
using Pearson’s chi-square (χ2) test and Fisher’s exact test
(when n < 5). The threshold for significant p values was
established as p < 0.05. Overall survival curves were esti-
mated by the method of Kaplan-Meier and data compared
using the log-rank test. Cases lacking one or more of the
clinicopathological variables were not included in the spe-
cific statistical analysis. Also, cases lacking TMA represen-
tation (core loss during immunohistochemical procedure
or lack of tumor in the TMA core) were excluded from
analysis.
Results
As shown in Table 1, HPV genotyping showed that HPV16
was present in 53.8 % (112/208) of cases, HPV18 was
present in 21.2 % (44/208), 11.5 % (24/208) of
Table 2 Detailed aspects for each antibody used in immunohistochemistry
Protein Antigen retrieval Antibody Antibody dilution and incubation time
MCT1 Citrate buffer (0.01 M, pH = 6), 98 °C, 20′ AB3538P 1:200, overnight
Chemicon International
MCT4 Citrate buffer (0.01 M, pH = 6), 98 °C, 20′ sc-50329 1:500, 2 h
Santa Cruz Biotechnology
CD147 EDTA (1 mM, pH = 8), 98 °C, 20′ sc-71038 1:400, overnight
Santa Cruz Biotechnology
GLUT1 Citrate buffer (0.01 M, pH = 6), 98 °C, 20′ ab15309-500 1:500, 2 h
AbCam
CAIX Citrate buffer (0.01 M, pH = 6), 98 °C, 20′ ab15086 1:2000, 2 h
AbCam
VEGF-A CC1 (pH = 8,2) Ventana VG-1 1:200, 60 min
AbCam
VEGF-C ptLink (pH = 9) Dako 18-2255 1:200, 60 min
Invitrogen
VEGF-D ptLink (pH = 9) Dako ab63068 1:50, 60 min
AbCam
VEGFR-1 ptLink (pH = 9) Dako ab9540 1:300, 60 min
AbCam
VEGFR-2 ptLink (pH = 9) Dako ab2349 1:100, 60 min
AbCam
VEGFR-3 ptLink (pH = 9) Dako ab72240 1:50, 60 min
AbCam
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cases showed infection with other HPV types and 21.6 %
(45/208) of cases showed no HPV infection. Also, some
cases showed infection by only one HPV type, while others
showed infection with 2 or 3 different HPV types.
The immunohistochemical evaluation showed that all
the metabolism-related proteins were expressed in the
cytoplasm, in the plasma membrane or exhibited both lo-
calizations in cancer cells. Interestingly, GLUT1 was also
present in the nucleus of 17 out of 197 cases (8.6 %). Fig. 1
shows photomicrographs representative of the expression
of each protein. As can be seen in Table 3, MCT4 and
CAIX were the proteins more frequently expressed at the
plasma membrane of cancer cells (around 85 %), followed
by MCT1 (59.2 %), GLUT1 (44.2 %) and, finally, CD147
(6.9 %). When evaluating the co-expression between the
proteins (Table 4), an association between MCT4 and
CAIX was found (p = 0.010).
Concerning the VEGF family members, overall, these
proteins, with the exception of VEGFR-1, presented a high
intensity and extension of expression in cancer cells (Fig. 2),
which implicated the use of a different cut-off (>5 instead
of >2) for the VEGF family in the subsequent analysis. As
can be seen in Table 3, VEGF-C and VEGFR-2 were the
VEGF family members more frequently expressed in can-
cer cells (around 90 %), followed by VEGF-A, VEGF-D and
VEGFR-3 (around 60 %) and, finally, VEGFR-1 (26.3 %).
When evaluating the co-expression between the expression
of the ligands and the receptors (Table 5), VEGF-A
was more frequently expressed in cancer cells express-
ing VEGFR-1 or VEGFR-3 (p = 0.008 and p < 0.001,
respectively), VEGF-C was more frequently expressed
in cancer cells expressing VEGFR-2 (p < 0.001), and
VEGF-D was more frequently expressed in cancer cells ex-
pressing VEGFR-1 or VEGFR-3 (p = 0.002 and p < 0.001,
respectively).
When evaluating the possible co-expression between
the metabolism-related and the VEGF family members
(Table 6), significant associations between MCT1 and
VEGF-A (p = 0.010), and MCT4 and both VEGF-A and
VEGFR-3 (p = 0.037 and p = 0.026, respectively) were
found.
Finally, the plasma membrane expression of the
metabolism-related proteins and the overall expression
of the VEGF family members were associated with the
Fig. 1 Immunohistochemical expression of MCT1, MCT4, CD147, GLUT1 and CAIX in cervical adenocarcinoma samples. Expression of proteins was
more frequently found in the plasma membrane of cells as shown in (a) for MCT1, (b) for MCT4, (c) for CD147, (d) for GLUT1 and (e) for CAIX. Nuclear
expression was also observed in some cases for GLUT1 (F)
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available clinicopathological data, with significant results
shown in Table 7. For the metabolism-related proteins, the
following associations were significant: (i) MCT4 and pres-
ence of parametrial invasion (p = 0.002) as well as HPV18
infection (p = 0.003); (ii) CD147 and presence of distant
metastasis (p = 0.044); (iii) GLUT1 and presence of distant
metastasis (p = 0.021); (iv) CAIX and smaller tumor size
(p = 0.036) as well as HPV18 infection (p = 0.004). For
the VEGF family members, the following associations
were significant: (i) VEGFR-1 and presence of local metas-
tasis (p = 0.027); (ii) VEGFR-1 and presence of lymphnode
metastasis (p = 0.030). Additionally, co-expression analysis
showed that the association of GLUT1 expression with
presence of distant metastasis was associated with co-
expression with MCT1, but not MCT4 (data not shown),
while co-expression of GLUT1 with MCT1 was also associ-
ated with presence of local metastasis, where 9/21 (42.9 %)
cases with local metastasis showed GLUT1/MCT1 co-
expression while 14/67 (20.9 %) cases without local metas-
tasis showed GLUT1/MCT1 co-expression (p = 0.046).
Also, when analyzing the clinicopathological value of
the significant co-expressions between metabolism-re-
lated proteins and VEGF family members (MCT1/
VEGF-C, MCT4/VEGF-A and MCT4 + VEGFR-3), co-
expression of MCT4 with VEGFR-3 was significantly as-
sociated with parametrial invasion, where 15/20 (75.0 %)
cases with invasion showed MCT4/VEGFR-3 co-expression
while 5/13 (38.5 %) cases without invasion showed MCT4/
VEGFR-3 co-expression (p = 0.036). Analysis of survival
showed no association with the different proteins studied
(data not shown).
Discussion
Tumor cell metabolic reprogramming and angiogenesis
stimulation are included in the well-known hallmarks of
cancer [7]. While angiogenesis has been studied for a
longer time and is included in the first group of hall-
marks of cancer [30], metabolic reprogramming of can-
cer cells is a much more recent research field. Although
some evidence points to a relation between these two
hallmarks [13], the crosstalk between metabolism and
angiogenesis is still poorly studied. Therefore, in the
present study, we characterized the metabolic and vascu-
lar profiles of a series of cervical adenocarcinomas, in an
attempt to provide additional evidence for the possible
crosstalk between these two important characteristics of
cancer cells.
The immunohistochemical evaluation revealed a high
frequency of expression of MCT4 and CAIX, an inter-
mediate frequency of MCT1 and GLUT1, and a low fre-
quency of CD147. Importantly, the high frequency of
MCT4, when compared with MCT1, indicates that this
MCT isoform should play an important role in the meta-
bolic reprogramming of cancer cells towards a hyperglyco-
lytic and acid-resistant phenotype. This contribution of
MCT4 probably goes in parallel with CAIX activity, as they
are significantly co-expressed. In opposition, GLUT1 ex-
pression does not account for the hyperglycolytic pheno-
type of all MCT4/CAIX positive tumors while CD147 does
not account for all MCT1 or MCT4 positive tumors. As a
result, another glucose transporter as well as another MCT
chaperone should also have a role in the metabolic adapta-
tions of cervical adenocarcinoma. The hypothesis of an al-
ternative MCT chaperone has already been raised in other
studies [31–34].
Interestingly, we found GLUT1 expression in the nu-
cleus. This is not the first report of GLUT1 in the nu-
cleus [35]; however, to the best of our knowledge, it is
Table 4 Associations between the metabolism-related proteins
CD147 GLUT1 CAIX
n Positive (%) p n Positive (%) p n Positive (%) p
MCT1 0.409 0.725 0.530
Negative 78 4 (5.1) 76 33 (43.4) 75 61 (81.3)
Positive 115 10 (8.7) 113 52 (46.0) 112 95 (84.8)
MCT4 0.695 0.793 0.010
Negative 25 2 (8.0) 21 9 (42.9) 21 13 (61.9)
Positive 171 12 (7.0) 170 78 (45.9) 169 143 (84.6)
Table 3 Expression frequencies of the studied proteins
n Expression Positive (%)
MCT1 196 116 (59.2)
MCT4 202 175 (86.6)
CD147 202 14 (6.9)
GLUT1 197 87 (44.2)
CAIX 192 158 (82.3)
VEGF-A 178 112 (62.9)
VEGF-C 179 162 (90.5)
VEGF-D 176 103 (58.5)
VEGFR-1 171 45 (26.3)
VEGFR-2 176 163 (92.6)
VEGFR-3 168 104 (61.9)
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the first report in the context of cancer. GLUT1 nu-
clear expression was found at a low frequency and with
no implications in prognosis; however, further studies
are required to understand the functional role of GLUT1
in this cellular compartment. GLUT1 nuclear expression
presented no association with clinicopathological param-
eters, but the same was not true for plasma membrane
expression of other markers.
MCT4 plasma membrane expression suggests an in-
crease in lactate efflux from cancer cells. As a result,
lactate will accumulate in the tumor microenvironment
and perform additional roles, including increase in tumor
cell motility as well as extracellular matrix remodeling
by stimulation of hyaluronan and its receptor CD44,
which are molecules involved in the process of cancer
invasion and metastasis [13, 36, 37]. These roles of lac-
tate in the extracellular milieu are in accordance with
the association of MCT4 expression with presence of
parametrial invasion. Besides the important role of extracel-
lular lactate, we should not forget that MCTs interact with
CD147 at the plasma membrane. This protein has been
firstly described thanks to its capability of increasing the
production of matrix metalloproteinases (MMP), having a
role in tumor invasion and metastasis [38]. As a result, by
interacting with CD147 at the plasma membrane, as well as
contributing for CD147 maturation and trafficking to the
plasma membrane [39, 40], MCTs are additionally involved
in cancer invasion and metastasis. In accordance with this
role of CD147, in the present study, we found a significant
association of this protein with presence of distant
Table 5 Associations between the VEGF family members
VEGFR-1 VEGFR-2 VEGFR-3
n Positive (%) p n Positive (%) p n Positive (%) p
VEGF-A 0.008 0.736 <0.001
Negative 63 10 (15.9) 62 58 (93.5) 62 26 (41.9)
Positive 100 35 (35.0) 98 93 (94.9) 97 72 (74.2)
VEGF-C 0.183 <0.001 0.281
Negative 12 1 (8.3) 13 8 (61.5) 12 6 (50.0)
Positive 154 44 (28.6) 148 142 (95.9) 145 95 (65.5)
VEGF-D 0.002 <0.001
Negative 69 10 (14.5) 70 61 (87.1) 64 28 (43.8)
Positive 96 35 (36.5) 91 89 (97.8) 91 73 (80.2)
Fig. 2 Immunohistochemical expression of VEGF family in cervical adenocarcinoma samples. (a) VEGF-A; (b) VEGF-C; (c) VEGF-D; (d) VEGFR-1; (e)
VEGFR-2; and (f) VEGFR-3
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Table 6 Associations of the metabolism-related proteins with the VEGF family members
VEGF-A VEGF-C VEGF-D VEGFR-1 VEGFR-2 VEGFR-3
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
MCT1 0.320 0.010 0.958 0.916 0.311 0.686
Negative 61 37 (60.7) 64 53 (82.8) 60 35 (58.3) 57 16 (28.1) 59 54 (91.5) 60 39 (65.0)
Positive 95 65 (68.4) 96 92 (95.8) 97 57 (58.8) 97 28 (28.9) 93 89 (95.7) 88 60 (68.2)
MCT4 0.037 0.699 0.878 0.319 0.359 0.026
Negative 21 9 (42.9) 22 21 (95.5) 22 13 (59.1) 22 8 (36.4) 22 22 (100.0) 21 9 (42.9)
Positive 137 91 (66.4) 140 125 (89.3) 136 78 (57.4) 134 35 (26.1) 134 124 (92.5) 128 87 (68.0)
CD147 0.138 0.122 0.074 0.187 1.000 0.223
Negative 146 91 (62.3) 149 136 (91.3) 147 82 (55.8) 145 39 (26.9) 143 134 (93.7) 138 89 (64.5)
Positive 13 11 (84.6) 13 10 (76.9) 12 10 (83.3) 11 5 (45.5) 11 11 (100.0) 12 10 (83.)
GLUT1 0.718 0.115 0.475 0.387 0.811 0.196
Negative 81 51 (63.0) 83 71 (85.5) 80 43 (53.8) 81 20 (24.7) 81 76 (93.8) 74 46 (62.2)
Positive 73 48 (65.8) 75 70 (93.3) 74 44 (59.5) 71 22 (31.0) 70 65 (92.9) 72 52 (72.2)
CAIX 0.876 0.740 0.135 0.982 0.818 0.149
Negative 25 16 (64.0) 26 24 (92.3) 25 11 (44.0) 25 7 (28.0) 26 24 (92.3) 26 14 (53.8)











metastasis. Previous studies have shown association of
CD147 with lymphnode metastasis in cervical cancer [41,
42] but, to the best of our knowledge, this is the first study
showing association with distant metastasis in cervical can-
cer. Following the rationale that hyperglycolytic and acid-
resistant tumors are associated with a more aggressive
phenotype [43], associations of GLUT1 and CAIX with
poor prognostic variables are expected. In fact, we found
GLUT1, alone or in combination with MCT1, but not
MCT4, to be associated with presence of distant metastasis.
Although GLUT1 has been previously associated with
lymphnode metastasis in cervical cancer [44], to the best of
our knowledge, this is the first report associating GLUT1
with distant metastasis in cervical cancer. This finding con-
tradicts another study in locally advanced cervical
carcinoma, where absence of GLUT1 was shown to sig-
nificantly increase the likelihood of metastasis-free sur-
vival [45]. It is important to highlight, however, that the
latter study was performed in a tumor series containing
only squamous cell carcinomas. Although MCT4 is
more frequently expressed in cervical adenocarcinomas
than MCT1, MCT1 also seems to have an important role
in the metabolic remodeling and aggressive behavior of
these tumors as, besides being associated with presence of
distant metastasis when co-expressed with GLUT1, MCT1
co-expression with GLUT1 is also associated with presence
of local metastasis. In fact, in a previous study, we show
that, in cervical adenocarcinomas, MCT1 co-expression
with CD147 is associated with presence of metastasis
(lymphnode and distant metastasis) [46]; however, in the
present study, only co-expression with GLUT1 showed sig-
nificant associations. Concerning CAIX, previous studies
on the clinicopathological significance of this pH regulator
in cervical cancer showed association with presence of dis-
tant metastasis [47], lymphnode metastasis, advanced
tumor stage, greater invasion depth and higher tumor
grade [48]. In the present study, these associations were
not found, probably because we focused only in adenocar-
cinomas, while the former studies considered tumors series
containing the different histological subtypes, with a major-
ity of squamous cell carcinomas. However, other associa-
tions were found for CAIX in the present study. CAIX was
more frequently expressed in smaller tumors, probably as a
response to initial tumor hypoxia (as CAIX is a target of
hypoxia-inducible factor (HIF) 1α [49]), before establish-
ment of the new blood vessel network.
Importantly, we found significant associations between
HPV18 infection and both MCT4 and CAIX. Although a
previous work found no association between CAIX ex-
pression and HPV status in head and neck squamous cell
carcinomas [50], MCT4 expression has been previously
associated with high-risk HPV in cervical cancer [31].
CAIX and MCT4 have the common feature of being HIF-
1α-induced key metabolic proteins [49, 51], and HPV
infection has been demonstrated to stabilize HIF-1α ex-
pression [52, 53]. Therefore, HPV may, indirectly through
HIF-1α, have a role in the metabolic reprogramming of
cancer cells, by stimulating, among other HIF-1α targets,
MCT4 and CAIX, key proteins in the hyperglycolytic and
acid-resistant phenotype of cancer cells. Importantly, HIF-
1α was recently described as a predictor of poor prognosis
in cervical cancer [54]. Further studies are required to elu-
cidate the specific mechanisms involved in this possible
stimulation since GLUT1, another HIF-1α target [55], was
not associated with HPV18 in this tumor series.
As mentioned above, lactate, besides being the product
of the predominant metabolic pathway shown by the ma-
jority of cancer cells, has important roles in the tumor
microenvironment, contributing to the malignant behavior
Table 7 Significant associations between plasma membrane
immunoexpression of the proteins analyzed and clinicopathological
data
n Positive (%) p
MCT4
Parametrial invasion 0.002
Absent 19 12 (66.7)
Present 26 28 (100.0)
HPV18 infection 0.003
Negative 143 119 (83.2)
Positive 39 39 (100.0)
CD147
Distant metastasis 0.044
Absent 95 3 (3.2)
Present 17 3 (17.6)
GLUT1
Distant metastasis 0.021
Absent 96 41 (42.7)
Present 18 13 (72.2)
CAIX
Tumor size 0.036
< 4 cm 25 24 (96.0)
> 4 cm 8 5 (62.5)
HPV18 infection 0.004
Negative 136 106 (77.9)
Positive 39 38 (97.4)
VEGFR-1
Local metastasis 0.027
Absent 51 8 (15.7)
Present 20 8 (40.0)
Lymphnode metastasis 0.030
Absent 49 9 (18.4)
Present 9 5 (55.6)
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of cancer cells [13]. One additional role of exogenous lac-
tate is the induction of VEGF [56], contributing to the an-
giogenic switch characteristic of tumor progression.
Following this line of evidence, we analyzed the expression
of VEGF family members in the cervical adenocarcin-
omas samples and verified its co-expression with the
metabolism-related proteins. Firstly, we observed an
overall high expression of these proteins, especially
VEGF-C and VEGFR-2. This ligand/receptor pair may
function together to stimulate either angiogenesis or
lymphangiogenesis [20], so this result is in accordance
with previous publications, where intense angiogenesis in
cervical adenocarcinomas [57] and high expression of
VEGF family members in cervical cancer is described [58].
When analyzing the co-expression of the metabolism-
related proteins with the VEGF family members, we found
associations between MCT1 and VEGF-C as well as MCT4
and both VEGF-A and VEGFR-3. These findings support
the previous study showing VEGF stimulation by lactate
[56], supporting the hypothesis of a crosstalk between the
metabolic remodeling of cancer cells and the angio-
genic switch. In respect to VEGF family members’ clini-
copathological significance, some previous studies show the
clinicopathological value of VEGF family members in cer-
vical adenocarcinoma, as VEGF-A, VEGF-C and VEGFR-3
were associated with lymphnode metastasis [58, 59]. Simi-
larly, in the present study, we found VEGFR-1 to be more
frequently expressed in cases with local metastasis or
lymphnode metastasis, supporting the value of VEGF
family members in prognosis. Finally, the association of
MCT4 with parametrial invasion was maintained when
co-expressed with VEGFR-3, indicating a probable co-
operation between metabolism and angiogenesis to en-
hance cancer cell aggressiveness.
Conclusions
In the present study, we found evidence pointing at a
crosstalk between two important hallmarks of cancer: de-
regulating cellular energetics and inducing angiogenesis.
Additionally, we reinforced the contribution of these hall-
marks to cancer progression and aggressiveness, and point
at promising therapeutic targets for cancer therapy, such
as MCTs. Further studies are warranted to confirm these
findings as well as characterize the metabolic and vascular
profile of other tumor types.
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